Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome associated with inflammatory bowel disease: Report of four patients

Shengyan Liu,M. Ma,Yuchen Liu,Chen Li

DOI: https://doi.org/10.1111/1756-185X.14565

2023-01-15

International Journal of Rheumatic Diseases

Abstract:Dear editor, Synovitis, acne, pustulosis, hyperostosis, and osteitis (SAPHO) syndrome is a chronic inflammatory disease characterized by osteoarticular and cutaneous involvement as its main manifestations.1 Inflammatory bowel disease (IBD) is a chronic inflammatory disease that mainly includes Crohn disease (CD) and ulcerative colitis (UC). The association between SAPHO syndrome and IBD has rarely been reported. In our initial SAPHO cohort of 164 patients, we did not observe SAPHO syndrome coexisting with IBD.2 With the increase of patient sample size, we found four cases of SAPHO syndrome associated with IBD among 1120 patients so far, which suggests a potential association between IBD and the autoinflammatory disease, SAPHO syndrome. Herein, we report four cases of SAPHO syndrome coexisting with IBD and summarize them in Table 1 and Figure 1. Patient 1: A 25yearold male presented with bilateral buccal and anterior chest acne since 2012. In 2016, he had abdominal pain and bloody stool and underwent colonoscopy; pathology suggested UC. Intravenous metronidazole, dexamethasone sodium phosphate enema, and oral mesalazine treatment were administered. In September 2018, he developed pain in the sternocostal joint, left wrist, right ankle joint, and bilateral knee joint. According to bone scans, SAPHO syndrome was diagnosed. Etanercept and salicylazosulfapyridine (SASP) were administered. One year later, the patient had recurrent UC. The symptoms improved after methylprednisolone combined with SASP. Patient 2: A 30yearold male had abdominal pain and bloody stool in 2014. UC was diagnosed based on colonoscopy and pathology. After SASP and mesalazine treatment, the patient only had intermittent recurrent symptoms. Seven years later, the patient presented with pain in the anterior chest wall and lumbar region. Based on the bone scan, the diagnosis of SAPHO syndrome was confirmed. The symptoms improved after methotrexate combined with prednisolone treatment. Patient 3: A 22yearold male developed facial acne in 2013 and was treated with minocycline. In 2019, he developed pain in the anterior chest wall, lumbar region, scapula, and clavicle. Based on bone scan, SAPHO syndrome was diagnosed. After adalimumab treatment, the acne had improved and bone pain was relieved. One year later, the patient developed diarrhea and hematochezia. Colonoscopy and pathology suggested UC, which was relieved after mesalazine enema treatment. Patient 4: A 58yearold male developed pain in the anterior chest wall and right knee in 2015. Biopsy showed aseptic osteomyelitis, and bone scan was also performed. SAPHO syndrome was diagnosed. Three months later, the patient developed abdominal pain and hematochezia. Colonoscopy and pathology suggested UC. After nonsteroidal antiinflammatory drugs and mesalazine treatment, symptoms of UC and SAPHO syndrome were relieved. SAPHO syndrome is a rare disease of unclear pathogenesis with an estimated annual prevalence of fewer than 10 in 100 000 in white individuals and 0.00144 in 100 000 in the Japanese population. In Taiwan, the prevalence of CD is 3.9 per 100 000, while the prevalence of UC is 12.8 per 100 000.3 The prevalence of SAPHO syndrome associated with IBD in our cohort of SAPHO syndrome was 0.36% (4 in 1120) and we did not observe SAPHO syndrome complicated with CD. Every SAPHO patient in our center underwent detailed history taking, examination, and regular follow up, but not every patient underwent colonoscopy for assessment, so the prevalence of IBD in our cohort may be underestimated. Kahn et al4 first reported the concurrence of IBD and SAPHO syndrome in patients in 1992. Naves et al5 showed that approximately 4.8% of patients with SAPHO syndrome have IBD, mostly CD, and colon involvement accounts for 92%. Although the etiology of IBD is unclear, it is thought to occur in genetically susceptible individuals, and chronic immune disorder ultimately leads to tissue damage. Extraintestinal manifestations of IBD occur in about onethird of patients, which are related to some autoimmune diseases.6 SAPHO syndrome can cause systemic inflammatory changes in multiple organs.7 The association between IBD and SAPHO syndrome has an immunological basis, and there is a potential link between them. The diagnosis of SAPHO syndrome is critical when it coexists with IBD. Considering that gastrointestinal symptoms do not parallel skin lesions and arthralgia, and that diagnosis of IBD is made earlier than SAPHO syndrome, SAPHO syndrome is more likely to be an extraintestinal manifestation of IBD or comorbidity. Extraintestinal

Medicine